Alfasigma Secures Exclusive Rights from Innovative Molecules to Parenteral Adibelivir for Treatment of HSV Encephalitis, an Ultra-Rare Disease
PR Newswire —
BOLOGNA, Italy and MUNICH, Jan. 14, 2026 /PRNewswire/ -- Alfasigma S.p.A. ("Alfasigma"), a global pharmaceutical company, and Innovative Molecules GmbH ("Innovative Molecules"), a clinical-stage biotechnology company, today announced a strategic partnership whereby Alfasigma will invest...